Introduction: Radical prostatectomy (RP) with pelvic lymph node dissection (PLND) is the standard treatment of high-risk prostate cancer. High-risk patients and those with lymph node metastasis (LNM) require further treatment. We review outcomes of RP+PLND in Kaiser Permanente Southern California (KPSC).
INTRODUCTION
Prostate cancer affects 1 in 6 men, making it the most common malignancy in men worldwide. 1 Because of improvements in screening and detection of prostate cancer in the era of prostate-specific antigen (PSA) testing, various treatment modalities dependent on a patient-physician shared decision-making process have been developed. Regarding more aggressive localized prostate cancer, radical prostatectomy (RP) is becoming the most prevalent treatment modality, primarily because of its lower morbidity rates as well as improved diseasefree and overall survival. [2] [3] [4] [5] [6] [7] As there continue to be more operations performed in patients with higher-risk localized prostate cancer, there has been an increasing number of cases of lymph node metastasis (LNM) discovered after RP. Optimal management of this subset of patients with high-risk prostate cancer is unknown and can be challenging to many urologists. One school of thought involves treatment of such patients with immediate androgen deprivation therapy after RP because it has an improved overall and biochemical recurrence-free survival. [8] [9] The risks of androgen deprivation, however, encourage many physicians to delay its use until evidence of prostate cancer recurrence has been established. An investigation of the Surveillance, Epidemiology and End Results (SEER) Program database showed that postponing and even omitting androgen deprivation therapy in men with positive lymph nodes after RP does not significantly influence survival. 10 Other investigators have shown that positive surgical margins may guide management of these higher-risk patients. 11 Although optimal management of lymph node-positive (LNP) patients remains controversial, the patient profile and histopathologic factors such as positive margin rate can help guide therapy. With improvements in biochemical testing, imaging, and advanced therapeutics, the 5-year survival rate in such patients is as high as 85%. 12 Nonetheless, results of large multi-institutional studies investigating this population have shown a poorer prognosis relative to their LNM-free cohorts, especially in cases with positive surgical margins. 13, 14 Daneshmand and colleagues 12 have shown that factors such as local tumor burden and percentage of lymph nodes involved with cancer influence disease progression. Other studies have reported a high Gleason score, seminal vesicle invasion, and positive margins as significant negative predictors of disease-free and overall survival in patients with LNM. [13] [14] [15] To further understand the pathophysiology of LNM, many investigations of risk factors for LNM in such populations have taken place. A retrospective review of the SEER database and the National Cancer Database showed that PSA, clinical stage, and African American race were strong predictors of LNM. Several important models predicting the risk of LNM, the most well known of which was developed by Briganti and colleagues, 16 have been used to guide surgical planning and prognostication in high-risk patients. However, these predictive models are limited by their inability to predict the clinical course of patients with LNM, especially in the setting of pathologic positive surgical margins.
The clinical course of patients with positive surgical margins and LNM on pathologic analysis after RP and pelvic lymph node dissection (RP+PLND) can be variable and is poorly understood. Many patients have a modest 10-year disease-free survival, whereas others exhibit early biochemical recurrence and progression. [13] [14] [15] Although disease progression and recurrence can depend on the volume of lymph nodes involved, management after prostatectomy of patients with LNM and positive surgical margins remains an unfamiliar territory to many urologists. In this study, we review the Kaiser Permanente Southern California (KPSC) experience with RP+PLND; specifically, we investigate the risk factors, pathologic outcomes, and clinical course of patients with and without LNM to better understand their management.
METHODS

Patient Population
This retrospective study was approved by the Kaiser Permanente Los Angeles Medical Center institutional review board. Demographic, clinical, and pathologic data were collected retrospectively from the medical charts of patients treated with radical prostatectomy for prostate cancer from January 1, 2001, to July 1, 2015. Patients older than age 18 years with pathologically confirmed prostate adenocarcinoma were included in the study. Surgery was performed at 3 of 9 hospitals in the KPSC Region. Robotic surgeries were included starting in 2008. Standard PLND was performed, including removal of common iliac, external iliac, hypogastric, and obturator lymph nodes. Preoperative data collected included PSA, ultrasound-guided transrectal biopsy pathology, and clinical stage determined by an attending urologist using the most recent American Joint Committee on Cancer staging system. Pathologic assessment was performed of the prostate biopsy specimen and RP specimens, and included the number of cores sampled, the number of positive cores, and stage using the most recent American Joint Committee on Cancer staging system. Follow-up included PSA testing, clinical examination according to the most recent National Comprehensive Cancer Network guidelines, and evaluation of patient charts for assessment of survival. Table 3 shows 5-year recurrence rates, use of adjuvant androgen deprivation therapy, and adjuvant radiation therapy use in each risk category. The recurrence rate was highest in the high-risk category (22%) and lowest in the low-risk category (12.1%). Adjuvant androgen deprivation use was also highest in the high-risk group (4.1%) and lowest in the low-risk group (0.9%). Patients with intermediate-risk prostate cancer had the highest rate of adjuvant radiation therapy (2.7%) relative to the low-risk (1.9%) and high-risk (2.5%) groups.
Statistical Analysis
ORIGINAL RESEARCH & CONTRIBUTIONS
Preoperative characteristics for patients with pathologic positive lymph nodes can be seen in Table 4 . Of the 1829 patients, 134 (7.3%) were LNP, and 1693 (92.6%) were lymph node negative (LNN). Patients with LNP were not significantly older than patients with LNN (60.7 vs 59.6 years, respectively). There were a larger number of patients with T2 and T3 disease in the LNP group (38.8% and 3.7%, respectively) relative to the LNN group (22.7% and 0.1%, respectively). Median PSA and Gleason score were significantly higher in the LNP group than in the LNN group (PSA, 10.5 ng/μL vs 6.5 ng/μL, p < 0.001; Gleason score, 7.3 vs 6.7, p < 0.001). There was a significantly larger percentage of patients with elevated Gleason scores in the LNP group (Table 4) . Further, a larger proportion of LNP patients received preoperative androgen deprivation therapy compared with LNN patients (11.2% vs 5.1%, respectively).
A comparison of postoperative data between LNP and LNN patients is seen in Table 5 . The positive margin rate was significantly higher in LNP patients than in LNN patients (23.1% vs 13.5%). Five-year overall survival was 86.9% in patients with positive surgical margins and 92.2% in patients with negative surgical margins. There was an increased prevalence of pathologic T3 disease in LNP patients (88.8% vs 25.4%, p < 0.001). Of note, 1 patient was noted to have T4 disease but did not have lymph node invasion. Gleason score upstaging was higher in LNP patients (35.1% vs 22.6%, p < 0.001). Gleason score downstaging was also higher in LNP patients; 
DISCUSSION
This study represents the largest retrospective prostatectomy cohort in KPSC. The study summarizes the preoperative and postoperative characteristics of patients who underwent RP+PLND for prostate cancer.
Of the patients who underwent RP, 13% were high risk, 51% were intermediate risk, and 35% were low risk. The percentage in each risk category is consistent with other prostate cancer databases . 11 The average prebiopsy PSA in the high-risk category was 13.3 ng/μL. In a recent study evaluating oncologic outcome in high-risk patients, the prebiopsy PSA was slightly higher at 15.9 ng/μL. 17 This difference may be attributable to aggressive PSA screening and shorter time to surgery caused by in-network care within a managed care system.
In our study, 17.8% of the high-risk, 14.8% of intermediate-risk, and 11.9% of low-risk patients had positive surgical margins after RP. Large RP series have reported a mean positive surgical margin rate ranging from 2% to 31%. [18] [19] [20] [21] The positive surgical margin rates are overall consistent with the literature. The slightly higher positive surgical margin rate in lowrisk patients in our series may be because of more aggressive nerve-sparing practices in this subset of patients. Differences in risk stratification between studies may also contribute to differences in positive surgical margin rates. Furthermore, LNP was 14.9% in high-risk, 9.8% in intermediaterisk, and 0.9% in low-risk RP recipients. Large multi-institutional studies have reported LNP ranging from 12.3% to 14% in high-risk patients, consistent with our findings. 18, [21] [22] [23] Of interest, our study showed a 5-year overall survival of 92.5% in high-risk patients with LNM. Five-year overall survival was 86.9% in patients with positive surgical margins and 92.2% in patients with negative surgical margins. Qin and colleagues 9 showed a cancer-specific survival of 96% in patients with LNM undergoing RP+PLND. Interestingly, all patients in the study received adjuvant androgen deprivation therapy, whereas only 5.2% of high-risk patients with LNM in our cohort underwent adjuvant androgen deprivation therapy. Additionally, 1.2% of patients without LNM received adjuvant androgen deprivation therapy (ADT). Although the influence of adjuvant ADT on survival was not particularly investigated in this study, it is noteworthy that there was no significant difference in 5-year overall survival given the pattern of adjuvant ADT use in patients with intermediate-risk and high-risk prostate cancer. Ideally, prospective randomized long-term studies with standardized criteria for adjuvant ADT would be necessary to investigate its influence on survival. It is clear that in our health care network, adjuvant ADT was administered on a case-by-case basis, taking into consideration margin positivity, LNM, timing and burden of disease recurrence, and patient-specific factors. Patients with positive surgical margins in the setting of LNM after RP+PLND require more aggressive follow-up and management. In our cohort, age, prebiopsy PSA and clinical T stage were factors associated with positive surgical margins in patients with LNP disease. Similar factors have been seen in other studies. 24 Although it is well known that patients with LNM and positive surgical margins have a worse prognosis, we investigated the factors influencing biochemical recurrence in this subset of patients. Age, biopsy Gleason score, Gleason score upstaging, and positive margins influenced biochemical recurrence (Table 7) . Of note, positive margin status was the most significant factor for biochemical recurrence (OR = 9.23, p < 0.001). Other investigations corroborated positive surgical margins as a strong factor of biochemical recurrence in prostatectomy recipients. [25] [26] [27] In the KPSC system, RP+PLND has been a standard of care for higher-risk prostate cancer patients. In our 15-year experience, patients with LNM have had more positive surgical margins, higher biochemical recurrence rates, and Gleason score upstaging. Although positive surgical margin was the most significant predictor of biochemical recurrence, it did not significantly influence 5-year survival. Our practice pattern in terms of how to manage patients with LNM and positive surgical margins has not been standardized and occurs on a case-by-case basis with multiple adjuvant treatments, including antiandrogen and radiation therapy.
Our study has several important limitations. First, this was a retrospective cohort study examining all patients who underwent RP for prostate cancer. Although the study is retrospective, the data on high-risk patients with LNM is valuable because randomized controlled trials are limited given the lower contemporary incidence of LNP disease with RP. Although it is limited in its design, the study does include pathologic data and 5-year followup with regard to adjuvant treatments and oncologic outcomes. We acknowledge that patient follow-up and data on recurrence rates and survival were limited to 5 years. Longer-term follow-up on overall survival, biochemical recurrence-free survival, and metastasis-free survival would add more value to modifying practice patterns at our institution. Lastly, data on patients who received preoperative or postoperative androgen deprivation therapy and adjuvant radiation therapy was not standardized. Despite this limitation, the influence of postoperative androgen deprivation on survival in high-risk patients with positive lymph nodes in this study remains consistent with the findings of large multiinstitutional studies.
CONCLUSION
To our knowledge, this study is the largest retrospective prostatectomy cohort summarizing preoperative and postoperative characteristics of patients with prostate cancer undergoing RP+PLND. Positive margin rates were 17.8%, 14.8%, and 11.9% in the high-, intermediate-, and low-risk groups. In multivariate analysis, age, prebiopsy PSA, and clinical stage were predictive of positive margins in patients with LNP disease. Furthermore, 
